Simulations Plus, Inc. (NASDAQ:SLP) Q2 2024 Earnings Call Transcript

Will Frederick: Certainly, with the Immunetrics acquisition, we do have an earn-out, so there are certain constraints within where we can fully integrate it, but we’ve made strides in the direction to leverage our existing sales force. You’ve heard us talk about the cross-selling, where can we leverage customers that we have to sell services, software from the different business units, continue to work up that value chain within the organization, hire decision makers. We still got about the same amount of sales and marketing folks. So there’s, I want to say, about 12 sales people, quota carrying, about 6 or 7 folks that are in marketing. And, certainly, a great addition, just recently, this last quarter with Dan Szot as our chief revenue officer. Shawn, anything I missed?

Shawn O’Connor: That sounds good. The consolidation process really started a couple of years ago. And at that time, before Immunetrics was pulling the resources from the divisions at the time, the previous acquisitions and consolidating them together into one sales and marketing organization that internally creates some efficiencies, but, more importantly, it was a focus in terms of our go-to-market presentation to our clients as one company. All of that leads to support to upsells and cross selling across platforms and across services to our existing customers. And I think that’s been accruing benefits here for a while.

Operator: There are no further questions in the queue. I’d like to hand it back to Mr. O’Connor for closing remarks.

Shawn O’Connor: Very good. Well, I appreciate everyone’s attention today and hope all was well on your side and look forward to speaking again soon. Take care all.

Operator: Ladies and gentlemen, this does include today’s teleconference. Thank you for your participation. You may disconnect your lines at this time and have a wonderful day.